Can Skin Sign and Symptoms be an Indicator of Excessive Antihyperlipidemic Treatment in Heart Failure Patients?

Abstract

Morbidities following antihyperlipidemic treatmenthave been reported in the literature. According to new guidelines high intensity antihyperlipidemic therapy is a class I recommendation for some disorders, although existing data regarding this therapy in symptomatic heart failure patients are equivocal. Evaluation of symptoms related to extreme antihyperlipidemic treatmentin heart failure patients is important, because it decreases the number of morbidities.